Government lifts ban on export of key APIs, vitamins

G Naga Sridhar Hyderabad | Updated on April 07, 2020 Published on April 07, 2020

Representative image   -  Reuters

The exports of these drugs were banned in March in the wake of Covid-19 outbreak and supply disruptions from China

In a major move, the Central Government has lifted the ban on export of key Active Pharmaceutical Ingredients (APIs) and formulations made from them.

In a notification, the Director General of Foreign Trade, Ministry of Commence & Industry has amended the Notification 50 dated March 3, 2020 which prohibited exports of 12 key APIs and Vitamins and formulations made out of them and made them `free' to be exported.

The products that are now eligible to be exported include Tinidazole, metronidazole, Acyclovir, Vitamins B1, B6, B12, Progesterone, Chloramphenicol, Erythromycin salts, ornidazole and formations made out of these products .

The exports of these drugs were banned in March in the wake of Covid-19 outbreak and supply disruptions from China. The move was aimed at ensuring no paucity of key APIs for India.

However, the Chinese manufactures have resumed the supply of raw materials to India about a couple of weeks ago.

The Pharmaceutical Export Promotion Council (Pharmexcil) on the behalf of its members also appealed to the Centre to remove the ban as it could harm the interest of Indian exporters.

With the removal of the ban, the exports are likely to increase significantly. The Covid-19 crisis, the ban on exports and the national lockdown have hit Indian pharma exports to the tune of $1.5 billion in the month of March as indicated by Pharmexcil data.

Published on April 07, 2020

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.